Selank is not approved by the U.S. Food and Drug Administration as a drug. Selank has been studied and may appear in pharmaceutical contexts outside the United States, but those activities do not establish FDA approval or apply to the Ryse laboratory-research product. FDA’s current safety-risk page lists selank acetate (TP-7) among substances withdrawn from Category 2 by their nominators and retains concerns about aggregation, peptide-related impurities, immunogenicity and limited human safety information. This wording specifically concerns selank acetate; the exact Ryse molecular form is not verified.
What Researchers Study This Peptide For
Published research has examined this peptide in laboratory, animal and, where available, human studies involving the following areas:
Evidence represented: Laboratory • Animal • Limited human
- Tuftsin-related peptide signalingMechanistic
- GABA-related pathwaysLaboratory and animal
- Gene-expression changesLaboratory and animal
- Animal stress and behavior modelsAnimal
- Learning and memory research modelsAnimal
- Immune-related signalingLaboratory and animal
- Limited anxiety-related clinical measurementsLimited human
These topics describe areas of scientific investigation. Findings vary by study design, research model, formulation and evidence quality and should not be interpreted as established human outcomes.
What should you know first?
What Is Selank?
Selank is a synthetic heptapeptide developed as an analog of tuftsin.
Researchers have examined nervous-system signaling, neurotransmission-related measurements, gene expression, behavioral models, immune-related expression, and learning or memory tasks. These study areas identify questions and measurements; they do not establish that a commercial product safely changes anxiety, mood or cognition in people.
What Is Tuftsin and How Is Selank Related?
Tuftsin is a naturally occurring four-amino-acid peptide associated with part of the immunoglobulin G heavy chain and studied in immune-cell signaling.
Selank is a seven-amino-acid synthetic analog that includes a tuftsin-related sequence extended with additional amino acids. The molecules are related but distinct, and results involving one should not automatically be assigned to the other.
The extension has been investigated in peptide-stability research without establishing superior safety or effectiveness.
Is Selank a Hormone?
Selank is generally described as a synthetic regulatory peptide rather than a classical full-length hormone.
Peptide classification describes structure and research context, not a human outcome. Product identity still requires analytical verification.
What Is GABA-Related Signaling?
GABA is an inhibitory neurotransmitter involved in regulating neuronal activity.
Laboratory studies have explored GABA-related gene expression, receptor-related signaling and interactions among neurotransmitter systems. Researchers should distinguish these measurements from direct receptor binding and from clinical outcomes; the available evidence does not support describing Selank as a natural benzodiazepine.
How Selank Is Studied
Researchers use biochemical assays, cell cultures, animal models, gene-expression analysis and defined human studies to answer different questions.
Laboratory findings identify possible mechanisms, animal studies test hypotheses in controlled models, and clinical studies evaluate predefined outcomes in specific populations. Findings remain tied to the material and conditions used.
- Biochemical assays and peptide-stability testing
- Cell and immune-related gene-expression models
- Animal behavioral and learning tasks
- GABA-, serotonin- and dopamine-related measurements
- Clinical rating scales in limited human publications
- Analytical identity and purity testing
Selank Versus Semax
Selank and Semax are often grouped together online, but they are different molecules with different sequences, origins and research histories.
Selank
- Synthetic heptapeptide
- Developed as a tuftsin analog
- Studied in behavioral, neurotransmission and immune-signaling contexts
- Limited human research exists
Semax
- Synthetic heptapeptide
- Developed from an ACTH-related fragment
- Studied in neurotrophic, gene-expression and neurological contexts
- Human and imaging research exists
What questions are researchers studying?
Published research has explored Selank through several laboratory, animal and limited human models.
These are categories of scientific investigation, not established product benefits.
- Tuftsin-related peptide biology
- GABA-related and other neurotransmission measurements
- Immune-related gene expression
- Animal behavioral and learning models
- Peptide stability and analytical identification
- Limited human anxiety-related clinical measurements
What should you know first?
Evidence status: primarily laboratory and animal research, with limited and geographically concentrated human evidence.
- Cell and molecular studies examine possible mechanisms.
- Animal models test hypotheses under controlled conditions.
- Human studies are few and mainly originate from Russia.
- Study quality, access to methodological detail and independent replication vary.
- A measured biological or rating-scale change does not automatically establish a general clinical benefit.
What do human studies tell us?
Most Selank publications are preclinical; a small human literature exists but should be interpreted cautiously.
Laboratory and animal work includes gene-expression studies, neurotransmission-related measurements, immune-related models, and behavioral tasks. Such work can generate hypotheses but does not establish the same result in people.
One publication involved 62 participants with generalized anxiety disorder or neurasthenia and compared Selank in about 30 participants with medazepam in 32. It was small, geographically concentrated and has limited independent replication.
The comparison does not establish equivalence to modern U.S. care or verify the Ryse product.
Foreign Pharmaceutical Research Versus Ryse Selank
Foreign clinical-study material and Ryse laboratory material belong to different product and regulatory contexts.
Foreign study material
- Developed and studied primarily outside the United States
- May have a defined formulation in a specific publication
- Findings apply to the studied material and conditions
- Regulatory status must be verified by jurisdiction
Ryse laboratory material
- Cataloged as Selank 20 mg vial
- Exact molecular form is unspecified
- Requires batch-specific analytical review
- Intended for laboratory research
Sharing the Selank name does not establish identical formulation, purity, manufacturing controls or pharmaceutical equivalence.
What are the limits of the current evidence?
The evidence base and regulatory record require several clear qualifications.
- Selank is not FDA approved in the United States.
- Much of the evidence is laboratory or animal research.
- Human evidence is small and geographically concentrated.
- Independent replication and methodological detail are limited.
- Biomarker or behavioral changes do not automatically establish clinical benefit.
- Results apply to the material and conditions used in each study.
- Tuftsin findings should not automatically be attributed to Selank.
- FDA’s retained safety language specifically names selank acetate, whose Category 2 nomination was withdrawn.
- A COA does not establish pharmaceutical equivalence or human safety.
Product Identity and Selank COA Documentation
A Selank label does not by itself verify exact molecular form, identity, purity, stability or untested quality attributes.
The repository verifies a Selank 20 mg vial catalog record and a generated label, but the catalog and label do not specify free base, acetate or another form. No product-specific Selank COA is registered.
Identity testing evaluates consistency with an expected molecule. HPLC separates detectable components under stated conditions and may support a relative-purity result.
Mass spectrometry can compare observed mass signals with an expected molecule. Content, salt form, sterility, endotoxin and stability are separate questions.
- Match the product, strength, batch or lot, laboratory and test date.
- Check whether sequence and molecular form are identified.
- Compare theoretical and observed molecular masses.
- Review chromatographic and mass-spectrometry evidence.
- Confirm identity, purity and content are separate results where tested.
- Read the report’s scope and limitations.
How should laboratories approach storage and handling?
Follow verified product-specific documentation and institutional procedures for the exact peptide and molecular form.
No product-specific storage temperature or exact molecular form was verified in the repository, so neither is supplied here.
- Maintain accurate batch identification.
- Record storage conditions, duration and transfers.
- Review stability information for the exact form.
- Protect material from environmental exposure where specified.
- Follow institutional handling and disposal procedures.
Frequently Asked Questions
What is Selank?
A synthetic seven-amino-acid peptide developed as a tuftsin analog.
What type of peptide is Selank?
It is generally described as a synthetic tuftsin-related regulatory heptapeptide.
What is tuftsin?
A naturally occurring four-amino-acid peptide studied in immune-cell and peptide-signaling research.
Is Selank a hormone?
It is generally described as a synthetic regulatory peptide, not a classical full-length hormone.
Why do researchers study Selank?
To examine tuftsin-related biology, gene expression, neurotransmission-related measurements, behavioral models and analytical identity.
Are there human studies involving Selank?
Yes, but the evidence is limited, geographically concentrated and has limited independent replication.
Is Selank FDA approved?
No. Selank is not approved by the U.S. Food and Drug Administration as a drug.
What is Selank’s current FDA compounding status?
FDA’s current safety-risk page lists selank acetate among substances withdrawn from Category 2 by their nominators and retains the previously identified safety concerns. This is not FDA drug approval.
Is Ryse Selank the same as pharmaceutical Selank?
No equivalence is established. Ryse Selank is separate laboratory material with an unspecified molecular form.
Is Selank the same as Semax?
No. Selank is tuftsin-related; Semax was developed from an ACTH-related fragment.
What does a Selank COA show?
A COA may report selected identifiers, methods and results for a defined sample and batch. No Selank COA is currently registered in this repository.
What does Research Use Only mean?
The material is intended for legitimate laboratory research where legally permitted, not for human or veterinary use.
Selected Selank Studies
External publications and regulatory materials are provided for scientific-literacy purposes. Foreign research, human studies or pharmacy-compounding review does not establish FDA approval, product equivalence, human safety, effectiveness or suitability for personal use.
Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
FDA’s current page retains selank-acetate safety concerns and lists it among Category 2 substances withdrawn by their nominators.
The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action
A mouse-spleen gene-expression study illustrating Selank’s tuftsin-analog and preclinical research context.
Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia
A small, geographically concentrated comparison involving 62 participants; it does not establish broad conclusions or product equivalence.
Research Use Only
Information on this page is provided solely for general scientific education and laboratory-research literacy. It is not medical or veterinary advice and does not provide dosing, reconstitution, administration or personal-use guidance.
Selank is not approved by the U.S. Food and Drug Administration as a drug. Foreign research, use or regulatory activity does not establish FDA approval or apply to the Ryse laboratory-research product.
FDA’s current safety-risk page retains concerns involving compounded selank acetate, including possible aggregation, peptide-related impurities, immunogenicity and limited human safety information; the substance is listed as withdrawn from Category 2 by its nominators. Compounding evaluation is not FDA drug approval.
The Ryse Selank product is separate laboratory-research material and is not represented as a foreign pharmaceutical product or an equivalent substitute for clinical-study material.
Ryse Peptides products are intended only for legitimate laboratory research where legally permitted. They are not intended for human or veterinary consumption or to diagnose, treat, cure, mitigate or prevent disease.